Our Alliance
Mission of the ILD Community Network
To unite, empower, and support individuals and organizations in advancing awareness, research, and care for those impacted by Interstitial Lung Disease.
Connect to ILD experts in your region
Partner with trusted ILD experts in your region to unlock your potential and achieve your goals.
ILD EXPERTS
Naomi Amudala
CRNP, MSN
Naomi Amudala, CRNP, MSN, is a highly experienced nurse practitioner specializing in rheumatology at Penn Medicine in Philadelphia, Pennsylvania. After graduating from MGH Institute of Health Professions in 2009 with a Master’s in Nursing, Naomi joined the division of Rheumatology at Boston University. Her primary focus was evaluating and managing patients with vasculitis as well as acting as co-investigator in multiple clinical trials in vasculitis. In 2018 she moved to Philadelphia and started working at Penn Medicine Rheumatology. The majority of her time continues to be dedicated to the clinical care of patients with vasculitis and other rare diseases as well as engaging in research. In 2022 Naomi joined the board of directors for RhAPP, which is a national organization for APPs and pharmacists in Rheumatology.
Christine Anderson
NP-C
Christine Anderson, NP-C, is a nurse practitioner specializing in pulmonology at Duke Health in Durham, North Carolina. She is originally from Canada and graduated from The University of Western Ontario with a Bachelors in Science in Nursing in London, Ontario back in 1999. After graduation, she moved to Durham, NC to start a nursing career at Duke University Health System. The majority of her nursing career has been in cardiology from Cardiac Step-Down to Cardiac Intensive Care Unit to the Cardiac Cath Lab. In 2005, Christine obtained a Masters in Science in Nursing with a Leadership focus and became the nurse manager of the Electrophysiology Lab at Duke Hospital. After downsizing the department, she moved over to the Duke Clinical Research Institute as a nurse clinician working on cardiology clinical trials. She truly missed patient care and went back to school and graduated with a post-master’s certificate as an Adult-Gerontologic Nurse Practitioner in 2015. Christine worked at Duke Cardiology of Lumberton for one year before coming back to main campus of Duke University Hospital and starting a new career in pulmonary medicine. Now she is the nurse practitioner for the Duke Interstitial Lung Disease Clinic where she still practices. For her last hurrah, Christine went back to school for a Doctorate of Nursing Practice degree that was awarded in 2019. Her graduate project was “Using a Smart Phrase to Improve Documentation of Supportive Care Measures in Patients with IPF”. This paper was published in the Journal for Nurse Practitioners and was presented at conferences such as the Pulmonary Fibrosis Foundation and Chest. Christine loves working with ILD patients and have learned so much over the past 9 years working in our clinic. She have been speaking about IPF and progressive ILD for past several years and have so much fun sharing my knowledge with Advanced Care Providers and providers alike.
Lisa Asfahani
PA-C
Lisa Asfahani DHSc, PA-C is a certified and state licensed Physician Assistant practicing in Rheumatology at Southland Arthritis in Temecula, California. Lisa graduated from California State Polytechnic University with a Bachelor’s degree in Biology, her Master’s degree in Physician Assistant Sciences from Loma Linda University in 2011 and her Doctorate degree in Health Sciences from A.T. Still University of Health Sciences in 2022. Lisa is experienced in both Rheumatology as well as in General Medicine and involved in numerous clinical studies in the field of Rheumatology. She is a member of several professional societies including the Association of Rheumatology Professionals (ARP), California Academy of Physician Assistants (CAPA), and RhAPP. Lisa’s goal in patient care is to treat each patient/provider interaction as an opportunity serve, to teach, and to heal. She enjoys traveling and spending time with family whenever she can.
Heather Bachert
NP
Heather D. Bachert, NP, is a board-certified Adult Nurse Practitioner and specializes in interstitial lung disease (ILD) and pulmonary fibrosis (PF) at Henry Ford Hospital in Detroit, Michigan. She earned her advanced practice training at Wayne State University and the University of Saskatchewan and is certified by the American Nurses Credentialing Center. In addition to her clinical role, Heather leads patient support groups for individuals living with ILD and PF, providing education, guidance, and a sense of community. Known for her compassionate and thorough approach, she is highly regarded by patients for her ability to explain complex conditions clearly and provide attentive follow-up care. She is currently accepting new patients and also offers telehealth services.
Shannon Benesh
DNP, NP-C
Shannon Benesh, DNP, RN-BC, AGNP-C, is a Nurse Practitioner specializing in Interstitial Lung Disease at Columbia University Irving Medical Center within the Division of Pulmonary and Critical Care. She earned her BSN from James Madison University and her MSN from Adelphi University, later completing her Doctor of Nursing Practice at Stony Brook University with a project focused on early advance care planning in ILD. Shannon has clinical experience as an RN at leading academic hospitals across various specialties and is certified as a Progressive Care Certified Nurse and Adult-Gerontology Nurse Practitioner. She is an active member of AANP, has contributed to published ILD research, and participates in national advisory boards dedicated to improving ILD care. She lives in Brooklyn with her husband and their dog and enjoys traveling, reading, running, and the occasional cocktail.
Kelley Brant
NP
Kelley Brant, NP, is a nurse practitioner specializing in pulmonology at Intermountain Health in Salt Lake City, Utah. With over 17 years of diverse clinical experience, Kelley Brant is a dedicated healthcare professional with a passion for advancing pulmonary care. A graduate of San Diego State University with a BSN, Kelley began her career as a registered nurse in high-acuity settings, including the emergency room, ICU, and urgent care, where she honed her ability to excel in fast-paced, multidisciplinary environments. Kelley earned her MSN from the University of South Alabama and is double board-certified as a Family Nurse Practitioner and Emergency Nurse Practitioner. For the past 2.5 years, Kelley has served as a nurse practitioner specializing in pulmonary medicine, with a particular focus in interstitial lung disease (ILD). As an ILD program coordinator, Kelley has gained experience in managing complex patient populations and remains actively involved in general pulmonary care, including COPD, asthma, and other respiratory conditions. Kelley also has a strong interest in research, supporting her facility’s participation in several randomized controlled trials to advance evidence-based practice. Beyond clinical work, Kelley is committed to fostering connections within the healthcare community. As a member of AANP, CHEST, and Utah Nurse Practitioners, she emphasizes professional development and collaboration to improve patient outcomes and advance the field of pulmonary care.
Michele Cerra
MSN, FNP-BC
April Conlon
NP-C
Kelsey Cramer
MSN, AGACNP-BC, DNP
Kelsey Cramer, MSN, AGACNP-BC, DNP, is a board-certified adult-gerontology acute care nurse practitioner specializing in pulmonary medicine at Froedtert & the Medical College of Wisconsin. She focuses on interstitial lung disease (ILD), pulmonary hypertension (PH), and sarcoidosis. Kelsey earned her MSN and DNP from Rush University and is dedicated to delivering patient-centered care, education, and support for those managing complex lung conditions.
Kristy Delaney
APRN
Kristy Delaney, APRN, is a pulmonary nurse practitioner specializing in interstitial lung disease at The University of Kansas Health System. She has over 21 years of experience in medicine, beginning her career as a bedside RN in the Medical ICU before becoming an APRN. For the past 9 years, she has focused her practice on ILD. In addition to her clinical expertise, Kristy holds a degree in Education and is passionate about empowering patients, caregivers, and fellow healthcare professionals through education and support in the management of ILD.
Rebekah Edwards
DNP, FNP-C
Rebekah Edwards, DNP, FNP-C, is a nurse practitioner specializing in pulmonology at Norton Thoracic Institute, St. Joseph’s Hospital and Medical Center in Phoenix, Arizona. She received her Bachelor of Science in Nursing from Arizona State University and is experienced in pulmonology, cardiology, and thoracic surgery. She also received her Doctorate of Nursing Practice from Arizona State University and has practiced in pulmonology ever since.
Mary Elliott
PA-C, PhD
Kathryn Fenwick
CRNP, DNP
Heather Finlayson
PA-C
Heather Finlayson, MS, PA-C, is a certified Physician Assistant specializing in rheumatology for Summit Rheumatology in Littleton, Colorado. She previously worked at National Jewish Health Rheumatology and started at Colorado Arthritis Associates in Rheumatology in 2012. She has also taught rheumatology courses at Rocky Vista University PA program since 2022. Heather is a member of the Association of Rheumatology Professionals (ARP) (division of American College of Rheumatology-ACR), and the Association of Women in Rheumatology (AWIR). She is currently the AWIR Denver Local Chapter Co-Lead, a Rheumatology Advanced Practice Providers (RhAPP) faculty member and has served on several ACR/ARP committees.
Cori Fratelli
MSN, FNP-C
Cori Fratelli, MSN, FNP-C, is a nurse practitioner specializing in pulmonology at National Jewish Health in Denver, Colorado. She has a unique background in both basic science and clinical research, which has informed her interest in clinical medicine. Her past basic science research includes asthma, airway hyperresponsiveness, cystic fibrosis, and lung cancer. Her past clinical research includes COPD and interstitial lung disease (ILD). Presently, she is interested in how research translates into personalized medicine. Her clinical focus is mainly on ILD, but she also sees general pulmonary medicine patients, as needed.
Kyle George
PA-C
Kyle George, PA-C, is a physician assistant with over 16 years of experience in rheumatology at Saint Luke's Medical Center in Boise, Idaho. He specializes in managing autoimmune diseases such as rheumatoid arthritis and osteoporosis. Kyle collaborates with a multidisciplinary team, providing personalized and comprehensive care to his patients.
Shannon Ghizzoni
PA-C
Shannon Ghizzoni, PA-C, is a board-certified Physician Assistant specializing in rheumatology at the Columbus Arthritis Center in Columbus, Ohio. With a passion for providing comprehensive care to patients with rheumatic conditions, Shannon focuses on patient education, disease management, and improving quality of life. She is dedicated to staying current with the latest advancements in rheumatology and fostering collaborative relationships with patients and healthcare teams to deliver personalized, evidence-based care.
Courtney Gibbons
NP
Courtney Gibbons, MSN, APRN, AGACNP-BC, is a dedicated Pulmonary Nurse Practitioner. With empathy, and compassion, Courtney is committed to delivering evidence-based, patient-centered care to individuals living with complex lung conditions. Her nurse practitioner career has been devoted to pulmonary medicine, to improve quality of life and empower patients. Courtney earned her License at Tyler Junior College then advanced to Registered Nurse in 2016 after completing her Bachelor of Science in Nursing at Indiana State University, and later earned her Master of Science in Nursing with an Adult-Gerontology Acute Care Nurse Practitioner Certification from the University of Texas at Arlington in 2021. Throughout her career, Courtney has been recognized for her dedication to clinical excellence and compassionate care, receiving the Houston Methodist ICARE Award and being named among the Houston Chronicle’s Top 150 Nurses of 2020.
Audrey Gibson
PA-C, MsPAS
Audrey Gibson, MSPAS, PA-C is a board-certified rheumatology physician assistant at the Arthritis Center of North Georgia in Gainesville, Georgia. She holds dual bachelor’s degrees in biology and psychology from Lipscomb University and earned her Master of Science in Physician Assistant Studies from South University in Savannah, Georgia. Audrey is a certified densitometrist with a clinical focus on rheumatoid arthritis, psoriatic arthritis, lupus, spondyloarthropathies, inflammatory myopathies, and osteoporosis. She is an active member of the Society of Physician Assistants in Rheumatology, the Georgia Society of Rheumatology, the American College of Rheumatology, and the American Academy of Physician Assistants. Audrey also serves as a faculty advisor for the Rheumatology Advanced Practice Providers (RhAPP).
Jessica Glennie
CNP
Jessica Glennie, CNP, is a certified nurse practitioner, specializing in pulmonology, who has worked in outpatient pulmonary medicine at the Cleveland Clinic in Cleveland, Ohio for 8 years. She manages patients in the interstitial lung disease program, including care of patients with idiopathic pulmonary fibrosis, autoimmune related interstitial lung disease, hypersensitivity pneumonitis, occupational lung diseases, and drug-induced interstitial lung disease. She is co-director of the Cleveland Clinic’s ILD multidisciplinary conference.
ILD Community Network Educational Events
Bridging APP Specialties: Tackling Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease
3rd Annual Rheumatology & Technology Symposium (ARTS)
August 27 @ 12:00 pm - August 29 @ 12:00 pm CT
Join us for The Advances in Rheumatology and Technology Symposium (ARTS), which returns Aug 27–29, 2026, in Chicago. ..
ILD Digital Learning Center
Podcasts
Podcasts
Podcast: Recognizing PH-ILD Earlier: Missed Signals, Delayed Diagnosis, and How to Close the Gap
February 2026
31:14 m
Pulmonary hypertension associated with interstitial lung disease (PH-ILD) is one of the most impactful—and often underrecognized—complications in patients with established ILD, frequently presenting with symptoms that mimic ILD progression. In this ILD Community Network podcast episode, Amanda Mixon is joined by Corinne Young to break down why PH-ILD is missed, what red flags clinicians should watch for, and when to escalate evaluation beyond “worsening ILD.” The discussion highlights practical screening cues such as disproportionate DLCO decline, stable imaging with worsening dyspnea, enlarged pulmonary arteries on high-resolution CT, and revealing echocardiogram findings including RV/RA enlargement, TAPSE, and tricuspid regurgitation—along with the limitations of echo estimates and the role of right heart catheterization for confirmation. Tune in for real-world strategies to improve earlier recognition, reduce diagnostic delays, and strengthen multidisciplinary collaboration between rheumatology, pulmonology, and primary care to improve outcomes for patients living with ILD and PH-ILD. #InterstitialLungDisease #PulmonaryHypertension #PHILD #Rheumatology #Pulmonology #AdvancedPracticeProviders #MedicalEducation #ILDCommunityNetwork #APAPP #RhAPP
ILD & PH-ILD at the Rheum–Pulm Crossroads
November 2025
22:52 m
Join host Amanda Mixon, President of RhAPP, for a special episode recorded live at the 6th Annual RhAPP Conference. In this conversation, Amanda is joined by Jessica Glennie, CNP, from the Cleveland Clinic, to explore the complex intersection of rheumatology and pulmonology, focusing on Interstitial Lung Disease (ILD) and Pulmonary Hypertension in ILD (PH-ILD). Together, they unpack how early recognition, multidisciplinary collaboration, and evidence-based management can improve outcomes for patients with connective tissue disease–related pulmonary complications. Tune in for expert insights, practical diagnostic tips, and highlights from one of the most engaging sessions of the RhAPP National Conference.
Evolving IPF Care: The Significance of Nerandomilast’s FDA Approval
October 2025
25:20 m
In this special crossover episode, host Amanda Mixon, PA-C, President of RhAPP, sits down with Corinne Young, FNP-C, founder and President of the Association of Pulmonary Advanced Practice Providers (APAPP), to discuss one of the most exciting developments in interstitial lung disease: the FDA approval of nerandomilast for idiopathic pulmonary fibrosis (IPF). This breakthrough marks the first new IPF therapy in more than a decade and introduces a novel PDE4B mechanism of action designed to reduce fibrosis and improve lung function. Together, Amanda and Corrine unpack the clinical data behind nerandomilast, key findings from the FIBRONEER-IPF trial, and how its safety profile—particularly reduced GI side effects—may reshape treatment pathways and patient quality of life. The conversation also highlights the overlap between rheumatology and pulmonology in managing fibrotic lung diseases and the importance of interdisciplinary collaboration as additional indications for progressive pulmonary fibrosis (PPF) are anticipated. #Rheumatology #Pulmonology #InterstitialLungDisease #IPF #Nerandomilast #Fibrosis #AdvancedPracticeProviders #APPs #FDAApproval #ClinicalUpdates
Rheumatology in the Lungs
July 2025
24:47 m
How can Advanced Practice Providers (APPs) in rheumatology and pulmonology collaborate more effectively to manage interstitial lung disease (ILD) and connective tissue diseases (CTDs)? In this engaging episode of the APAPP Broadcast, recorded live at the Second Annual National APAPP Conference in Nashville, experts Jessica Glennie, PA-C (Cleveland Clinic), Amanda Mixon, PA-C (Colorado), and Cori Fratelli, NP (National Jewish Health) explore clinical overlaps between autoimmune rheumatic diseases and lung involvement, such as ILD in rheumatoid arthritis, systemic sclerosis (scleroderma), Sjögren’s syndrome, and myositis. The panel shares clinical pearls on: -How to recognize signs of CTDs in pulmonary patients -The importance of labs and imaging in early diagnosis -What rheumatology APPs should ask about pulmonary symptoms -The power of cross-specialty collaboration -Real-world case insights, including navigating bird-related hypersensitivity pneumonitis
Immunology of the Lung Podcast
July 2025
11:40 m
Tune in from the Annual APAPP National Conference for a dynamic episode of the APAPP Podcast featuring Corinne Young, FNP-C, Amanda Michaud, PA-C, and Brian Bizik, PA-C—three expert APPs leading engaging sessions on lung immunology, rare immune deficiencies, and COPD updates. Amanda breaks down the “Immunology of the Lung 101” and her “Finding the Zebras” series, where she highlights key red flags for primary immune deficiencies, sharing real patient cases and diagnostic tips to help clinicians recognize and manage these commonly missed conditions. Brian shares practical takeaways from the latest GOLD COPD guidelines, including how biomarkers like eosinophil counts can guide personalized inhaled corticosteroid decisions. Whether you're managing patients with asthma, COPD, or unexplained recurrent infections, this episode delivers clinical pearls you can apply in your practice right away. Discover why this APP-led meeting stands out as a must-attend event for pulmonary and immunology providers. Be sure to like, subscribe, and follow us for more expert-driven conversations.
ILD 101, ILD 102, ILD Peds
July 2025
20:57 m
Join Jessica Glennie, APRN, Naomi Miyazawa, PA-C, and Cori Fratelli, FNP, from the 2025 APAPP National Conference as they explore pediatric and adult interstitial lung disease (ILD). This episode covers diagnosis, disease progression, anti-inflammatory and anti-fibrotic therapies, and the importance of multidisciplinary care. Learn about pediatric ILD (CHILD), autoimmune-related ILD, and new treatment guidelines—all through real-world clinical insights.
Advancing ILD & PH-ILD Care
July 2025
21:35 m
Join Jessica Glennie, APRN, and Lori Reed, FNP, from the 2025 APAPP National Conference as they discuss key insights in diagnosing and managing interstitial lung disease (ILD) and pulmonary hypertension (PH). From interpreting PFTs and recognizing red flags to exploring current and emerging therapies like inhaled treprostinil and neuredomast, this episode offers practical strategies for improving patient care. Tune in for expert tips and updates every pulmonary provider should know.
Practical Considerations for Screening for PH in ILD Clinics
July 2025
17:17 m
In this insightful Podcast, expert advanced practice providers, Corinne Young & Jessica Glennie share practical strategies for identifying and screening for pulmonary hypertension (PH) in patients with interstitial lung disease (ILD). They discuss how to recognize subtle red flags—such as declining DLCO, changes in walk test performance, and discrepancies in pulmonary function test results—that may indicate the presence of PH. The conversation also covers when to order echocardiograms, when to refer for right heart catheterization, and how to distinguish ILD progression from the development of PH. With a focus on multidisciplinary collaboration and real-world clinical workflows, this episode offers valuable, actionable guidance for APPs, pulmonologists, and care teams managing ILD populations.
Understanding MAC with Jennifer Faber- Gerling
December 2024
30:30 m
In this episode, Corinne Young interviews Jennifer Faber- Gerling about mycobacterium avian complex (MAC). They discuss the bacterium itself, the rise in cases, screening and diagnosis, treatment and side effects, reinfection versus reactivation, and symptom management. Jennifer emphasized the importance of close surveillance, collaboration with a multidisciplinary team, and individualized care for patients with MAC.
Idiopathic Shortness of Breath Part 1 Using CPET
December 2024
26:37 m
National Jewish Health’s NP, Cori Fratelli, shares with us how she and her colleagues utilize CPET and other testing in patients with unexplained shortness of breath.
Idiopathic Shortness of Breath part 2 Dysfunctional Breathing Clinic
December 2024
29:41 m
Nurse practitioner Cori Fratelli from National Jewish Health discusses breathing pattern disorders, related to unexplained dyspnea. Cori advocates to consider these disorders, discusses treatment methods like breath retraining, inspiratory muscle training, and emphasizes the need for more research and specialized clinics.
Deep Dive Into ILD Therapeutics
December 2024
37:59 m
Check out this podcast recording from the 2024 APAPP Conference in Vegas!
FAQ
FAQ
How can clinicians distinguish PH-ILD from progression of interstitial lung disease alone?
February 2026
08:11 m
In this clinical update, Jessica Glennie, CNP, from the Cleveland Clinic Interstitial Lung Disease Group, explains how to differentiate worsening interstitial lung disease (ILD) or progressive pulmonary fibrosis (PPF) from developing or worsening pulmonary hypertension (PH). Because patients often present with overlapping symptoms such as shortness of breath, fatigue, and decreased exercise tolerance, she outlines a practical diagnostic approach using NT-proBNP, spirometry (FVC), DLCO trends, the FVC/DLCO ratio, six-minute walk testing, high-resolution CT imaging, echocardiogram findings (including RVSP and TAPSE), and when to consider right heart catheterization. This concise review helps clinicians determine whether pulmonary hypertension or ILD progression is driving a patient’s decline and supports more informed clinical decision-making.
What Were The Key Findings From the FIBRONEER-IPF Study?
October 2025
03:51 m
In this FAQ video, Corinne Young, FNP-C, founder and president of the Association of Pulmonary Advanced Practice Providers (APAPP), breaks down the pivotal FIBRONEER-IPF Phase 3 trial evaluating nerandomilast, a novel oral PDE4B inhibitor for patients with idiopathic pulmonary fibrosis (IPF). This randomized, double-blind, placebo-controlled study assessed nerandomilast both as monotherapy and in combination with existing antifibrotic therapies such as pirfenidone and nintedanib. Over 52 weeks, investigators observed that nerandomilast slowed lung function decline (FVC), reduced exacerbations and hospitalizations, and demonstrated a safety profile comparable to placebo, with notably fewer gastrointestinal side effects than traditional antifibrotics. These findings mark an exciting advancement in IPF management, offering clinicians a new therapeutic option that may improve both tolerance and long-term outcomes. #IPF #Nerandomilast #FIBRONEERIPF #Pulmonology #AntifibroticTherapy #PDE4B #InterstitialLungDisease #AdvancedPracticeProviders #APPs #ClinicalTrials #FDAApproval
Med Review
Med Review
Recommended Dosing Strategy For Nerandomilast and Key Adverse Effects To Watch For
December 2025
03:42 m
In this medication review, Corinne Young, Pulmonary Nurse Practitioner and President of the Association of Pulmonary Advanced Practice Providers (APAPP), provides a clear overview of nerandomilast, a newly approved therapy for idiopathic pulmonary fibrosis (IPF). Corinne explains recommended dosing strategies—including 18 mg twice daily as the target dose—along with when to use alternative dosing in combination with pirfenidone or nintedanib, and important considerations for patients taking CYP3A inhibitors. She also reviews the key adverse effects clinicians should monitor, including diarrhea, GI symptoms, mood changes, fatigue, dizziness, headache, and potential allergic reactions. This concise breakdown helps clinicians understand how to dose nerandomilast safely, manage side effects, and optimize treatment for patients with IPF. #IPF #IdiopathicPulmonaryFibrosis #PulmonaryCare #Nerandomilast #IPFTreatment #PulmonaryFibrosis #InterstitialLungDisease #ILD #APPeducation #PulmonaryAPP
Webcast
Webcast
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease
April 2026
41:28 m
This webcast brings together rheumatology and pulmonology experts to explore the recognition and management of interstitial lung disease (ILD) in patients with autoimmune conditions, using real-world case discussions to guide clinical decision-making. Through cases of rheumatoid arthritis–associated ILD and systemic sclerosis with progressive pulmonary fibrosis, Mary Elliott, PA-C, PhD and Alanna Kavanaugh, EdD(c), FNP-BC, MSN, BSN, CCRN highlight key risk factors, early clinical signs such as dyspnea and inspiratory crackles, and the importance of diagnostic tools including pulmonary function tests and high-resolution CT imaging. The discussion emphasizes identifying high-risk patients, understanding imaging patterns like usual interstitial pneumonia (UIP), and initiating timely, evidence-based treatment strategies. The session also examines evolving treatment approaches, including immunosuppressive therapies, antifibrotic agents, and biologics, while addressing common clinical dilemmas such as methotrexate use and therapy selection. A strong focus is placed on multidisciplinary collaboration, ongoing monitoring, and individualized patient care, including considerations for transplant referral and supportive interventions. Overall, this webcast provides a practical, case-based overview to help clinicians improve early detection, optimize management, and better coordinate care for patients with autoimmune-related ILD.
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease
April 2026
20:51 m
This webcast presents a case-based discussion on recognizing and managing interstitial lung disease (ILD) in patients with rheumatic conditions, including rheumatoid arthritis and systemic sclerosis. Through real-world patient scenarios, Wendy Simmons, PA-C, DFAAPA and Christine Anderson, NP-C highlight key risk factors such as seropositivity, age, and progressive respiratory symptoms, along with important findings like inspiratory crackles and exertional desaturation. The session emphasizes early detection using pulmonary function tests and high-resolution CT imaging, identification of fibrotic patterns like UIP, and timely initiation of immunomodulatory and antifibrotic therapies. The importance of multidisciplinary collaboration, proactive monitoring, and early referral for transplant evaluation and supportive care is reinforced to help preserve lung function and improve patient outcomes.
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease
April 2026
23:32 m
This webcast provides a case-based discussion on recognizing and managing interstitial lung disease (ILD) in patients with rheumatic diseases, including rheumatoid arthritis and systemic sclerosis. Through real-world patient scenarios, Robert Laugherty, PA-C and Erica Ludtke, NP highlight key risk factors such as high serologic titers, age, and progressive respiratory symptoms, along with important findings like inspiratory crackles and exertional desaturation. The session emphasizes early screening with pulmonary function tests and high-resolution CT imaging, identification of fibrotic patterns like UIP, and timely initiation of immunomodulatory and antifibrotic therapies. The importance of close collaboration between rheumatology and pulmonology, early intervention, and proactive monitoring is reinforced to help slow disease progression and improve patient outcomes.
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease
April 2026
19:51 m
This webcast features a case-based discussion on recognizing and managing interstitial lung disease (ILD) in patients with rheumatic conditions, including rheumatoid arthritis and systemic sclerosis. Through practical clinical scenarios, Iris Zink, MSN, ANP-BC, APRN and Heather Bachert, MSN, ANP-BC highlight key risk factors such as high serologic markers, age, and progressive respiratory symptoms, along with important findings like inspiratory crackles and exertional desaturation. The session emphasizes early detection using pulmonary function tests and high-resolution CT imaging, identification of fibrotic patterns like UIP, and timely initiation of immunomodulatory and antifibrotic therapies. The importance of multidisciplinary collaboration, early referral for transplant evaluation, and supportive interventions such as pulmonary rehabilitation is reinforced to help preserve lung function and improve patient outcomes.
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease
April 2026
13:12 m
This webcast presents a case-based discussion on recognizing and managing interstitial lung disease (ILD) in patients with rheumatic conditions, including rheumatoid arthritis and systemic sclerosis. Through real-world patient cases, Janine Shinn, PA-C and Jasmine McElhany, PA highlight key risk factors such as age, seropositivity, and progressive respiratory symptoms, along with important findings like inspiratory crackles and exertional desaturation. The session emphasizes early screening with pulmonary function tests and high-resolution CT imaging, identification of high-risk patterns like UIP, and timely initiation of immunomodulatory and antifibrotic therapies. The importance of multidisciplinary collaboration, proactive monitoring, and early referral for advanced care is reinforced to help improve patient outcomes.
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease
April 2026
33:58 m
This webcast presents a case-based discussion on identifying and managing interstitial lung disease (ILD) in patients with rheumatic conditions, including rheumatoid arthritis and systemic sclerosis. Through real-world patient scenarios, Amanda Sell, PA-C and Kelsey Cramer, AGACNP-BC, DNP highlight key risk factors such as high serologic titers, age, and progressive respiratory symptoms, along with important clinical findings like inspiratory crackles and exertional desaturation. The session emphasizes early screening with pulmonary function tests and high-resolution CT imaging, recognition of fibrotic patterns like UIP, and timely initiation of immunomodulatory and antifibrotic therapies. The discussion also underscores the importance of multidisciplinary collaboration, proactive monitoring, and early referral for advanced care, including transplant evaluation, to improve patient outcomes.
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease
April 2026
29:09 m
This webcast offers a case-based exploration of identifying and managing interstitial lung disease (ILD) in patients with rheumatic diseases, including rheumatoid arthritis and systemic sclerosis. Through real-world patient scenarios, clinicians Lori Reed, NP and Audrey Gibson, PA-C highlight key risk factors such as high serologic titers, age, and progressive respiratory symptoms, along with important clinical findings like inspiratory crackles and exertional desaturation. The discussion emphasizes early detection using pulmonary function tests and high-resolution CT imaging, recognition of fibrotic patterns like UIP, and timely initiation of immunomodulatory and antifibrotic therapies. The session also underscores the importance of multidisciplinary collaboration, proactive monitoring, and comprehensive patient care to help slow disease progression and improve outcomes.
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease
April 2026
21:10 m
This webcast provides a case-based overview of identifying and managing interstitial lung disease (ILD) in patients with rheumatic diseases, including rheumatoid arthritis and systemic sclerosis. Through practical clinical scenarios, experts Michele Cerra, MSN, FNP-BC and Christine Anderson, NP-C highlight key warning signs such as progressive shortness of breath, fatigue, and exertional desaturation, along with high-risk features like seropositivity and diffuse disease. The discussion emphasizes early diagnosis using pulmonary function tests and high-resolution CT imaging, recognition of fibrotic patterns like UIP, and timely initiation of immunomodulatory and antifibrotic therapies. The session also underscores the importance of multidisciplinary collaboration, proactive monitoring, and comprehensive supportive care to improve patient outcomes.
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease
April 2026
37:44 m
This webcast provides a practical, case-based look at identifying and managing interstitial lung disease (ILD) in patients with autoimmune conditions, with a focus on rheumatoid arthritis and systemic sclerosis. Through real-world scenarios, expert clinicians, Betsy Kirchner, DNP and Jessica Glennie, MSN, APRN highlight key risk factors, early warning signs like exertional dyspnea and inspiratory crackles, and the importance of timely screening with pulmonary function tests and high-resolution CT imaging. The discussion emphasizes collaborative care between rheumatology and pulmonology, outlining treatment strategies that balance immunosuppression and antifibrotic therapy to slow disease progression. Attendees will gain actionable insights on early detection, multidisciplinary management, and optimizing patient outcomes in ILD.
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Diseas
April 2026
30:14 m
This webcast features a case-based discussion exploring the critical connection between rheumatologic diseases and interstitial lung disease (ILD), emphasizing early recognition, risk stratification, and collaborative care. Through real-world patient cases—including rheumatoid arthritis–associated ILD and systemic sclerosis–related lung involvement—experts, Iris Zink, MSN, ANP-BC, APRN and Heather Bachert, MSN, ANP-BC, highlight key clinical warning signs such as progressive dyspnea, fatigue, and high-risk serologic markers. The session underscores the importance of timely screening with pulmonary function tests and high-resolution CT imaging, as well as early referral to pulmonology. Treatment strategies are reviewed, including the role of immunomodulators and antifibrotic therapies in slowing disease progression. Ultimately, this discussion reinforces the need for multidisciplinary management and proactive monitoring to improve outcomes and quality of life for patients with autoimmune-related lung disease.
Emerging Therapies in ILD
October 2025
07:37 m
In this presentation, Corinne Young reviews the latest advances in therapies for interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF), highlighting the promising results of nerandomilast, a phosphodiesterase-4B inhibitor with both antifibrotic and immunomodulatory effects. Phase 3 trials (FIBRONEER-IPF and FIBRONEER-ILD) demonstrated that twice-daily nerandomilast slowed lung function decline and improved outcomes across patient populations, including those with autoimmune-related disease. The discussion also covers the drug’s safety profile—showing fewer gastrointestinal side effects compared to existing antifibrotic agents—and emerging treatments such as inhaled treprostinil, which is being studied for pulmonary fibrosis beyond pulmonary hypertension. With multiple new agents and combination therapies on the horizon, these developments represent meaningful progress in the treatment and management of fibrotic lung disease.
Antifibrotic Therapy
October 2025
06:40 m
In this session, Corinne Young reviews the evolution of antifibrotic therapies for interstitial lung disease, beginning with the 2015 U.S. approval of pirfenidone (Esbriet) for idiopathic pulmonary fibrosis (IPF). Pirfenidone works by targeting TGF-β and TNF-α to slow fibroblast proliferation and collagen synthesis, though patients often experience gastrointestinal side effects and fatigue. The discussion also covers nintedanib (Ofev), a tyrosine kinase inhibitor that blocks multiple growth factor pathways (VEGF, FGF, PDGF) and is now approved for both IPF and other progressive fibrotic lung diseases. Clinical trials such as CAPACITY, ASCEND, INPULSIS, and INBUILD demonstrated that these antifibrotics significantly slow the rate of lung function decline and disease progression. The talk concludes by emphasizing careful side-effect management, liver monitoring, and appropriate patient selection to optimize outcomes with these cornerstone antifibrotic therapies.
The Rheum-Pulm Interface: Bridging Specialties in SARD-ILD
October 2025
11:21 m
In this session, Corinne Young and Wendy Simmons highlight the importance of a multidisciplinary approach to managing interstitial lung disease (ILD) in patients with systemic autoimmune and rheumatologic disorders. Collaboration between rheumatology, pulmonology, and radiology teams is key to early recognition, diagnosis, and treatment planning—especially given the high risk of ILD-related morbidity and mortality in conditions like systemic sclerosis, rheumatoid arthritis, lupus, and Sjögren’s syndrome. The discussion reviews ACR screening guidelines, emphasizing the role of high-resolution CT imaging, pulmonary function testing, and oxygen desaturation monitoring. It also covers evidence-based first-line and escalation therapies, including mycophenolate, cyclophosphamide, and rituximab, while underscoring the need for frequent assessment, early intervention, and coordinated care to improve patient outcomes.
Understanding the Landscape of ILD: Burden, Pathophysiology, and Classification
October 2025
20:49 m
In this presentation, pulmonary nurse practitioner Corinne Young and rheumatology physician assistant Wendy Simmons explore the complex relationship between interstitial lung disease (ILD) and connective tissue diseases (CTDs). Together, they provide a multidisciplinary perspective—highlighting how collaboration between pulmonology, rheumatology, and radiology leads to earlier diagnosis, better management, and improved outcomes. The session covers ILD classifications, common causes such as autoimmune disorders, environmental exposures, and drug toxicities, as well as diagnostic tools including high-resolution CT imaging, pulmonary function testing, and serologic assays. The speakers also discuss the importance of recognizing progressive phenotypes, understanding imaging patterns like UIP and NSIP, and tailoring therapy based on disease behavior. This session emphasizes that in ILD, time is lung—early recognition and coordinated care are essential to preserving function and extending quality of life.
IPF & PPF: Natural History, Diagnosis, and Management
October 2025
07:52 m
In this educational session, Corinne Young breaks down the underlying mechanisms, progression, and management of idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). The discussion covers common genetic and environmental risk factors—including family history, smoking, and occupational exposures—and explains how chronic inflammation leads to fibrosis and loss of lung elasticity. Listeners gain a clear understanding of how progressive pulmonary fibrosis is identified through lung function tests (FVC, DLCO) and imaging changes over time. The presentation also addresses treatment strategies, highlighting when corticosteroids may be appropriate, why long-term steroid use is limited, and how newer antifibrotic and immunomodulatory therapies are improving outcomes for patients with fibrotic lung disease.
Rheumatoid Arthritis Associated ILD, End Stage Therapy, and Multidisciplinary Care
October 2025
02:31 m
In this discussion, Corinne Young explores the complexities of managing patients with advanced interstitial lung disease, emphasizing the importance of early referral for lung transplant and cautious evaluation of unproven stem cell therapies. The conversation highlights how patients are sometimes misled into costly, non-evidence-based treatments abroad and underscores that only limited data exist for hematopoietic stem cell use in this setting. The speakers stress the critical role of multidisciplinary collaboration among pulmonology, rheumatology, gastroenterology, and cardiology teams, along with early conversations about palliative care and quality-of-life goals. With new therapies emerging, the focus remains on preserving lung function, aligning treatment with patient priorities, and ensuring compassionate, coordinated care for those facing progressive disease.
What Can Pulmonology APPs Do Once They've Established an ILD Diagnosis to Aid in Potential Rheumatology Workups?
July 2025
01:42 m
Once you've confirmed a diagnosis of interstitial lung disease (ILD), what’s next? In this practical and fast-paced discussion, Amanda Mixon, PA-C, shares actionable steps for evaluating patients for underlying autoimmune or connective tissue diseases. Learn what symptoms to ask about—joint pain, morning stiffness, skin lesions, Raynaud’s, dry eyes or mouth—and how labs and rheumatology collaboration can support early detection and accurate diagnosis. This video offers clinical pearls for APPs working in pulmonology who want to strengthen their diagnostic acumen and build better cross-specialty communication with rheumatology colleagues. Topics covered: – What symptoms may signal underlying rheumatic disease in ILD patients – Key lab tests to guide your differential – When to refer to rheumatology – The value of real-time collaboration across specialties ILD care is better together. Watch now to improve your approach to autoimmune workups in pulmonary patients.
Scleroderma Treatment
July 2025
01:52 m
In this focused discussion, Amanda Mixon, PA-C shares a practical approach to managing patients with systemic sclerosis (Scleroderma), with an emphasis on individualized care based on disease manifestation. From echocardiograms to pulmonary imaging, medication choices to vascular complications, this talk provides key insights into how APPs can tailor care to improve outcomes. Learn how to approach limited vs. diffuse Scleroderma, when to avoid glucocorticoids, and how to manage complications like digital ulcers and pulmonary involvement. Key takeaways include: – When to use echocardiograms, CT scans, and other diagnostics – Medication strategies: Mycophenolate, Selenomab, CCBs, ARBs, and more – Avoiding glucocorticoids in diffuse disease and managing risk of renal crisis – Treating symptomatically: digital ulcers, skin fibrosis, and blood flow support This is a must-watch for APPs in rheumatology, pulmonology, or primary care managing patients with Scleroderma.
Systemic Sclerosis Presentation
July 2025
11:52 m
In this powerful and personal clinical reflection, Amanda Mixon, PA-C, shares her journey treating patients with diffuse systemic sclerosis (Scleroderma), including key lessons learned from working at a major Scleroderma center at Northwestern. From building trust with colleagues to managing life-threatening complications like Scleroderma Renal Crisis, this video offers invaluable insights for APPs and clinicians navigating this complex autoimmune disease. You’ll hear firsthand experiences treating patients with severe skin involvement, pulmonary fibrosis, digital ulcers, GI complications, and early vasculopathy. Learn why RNA polymerase III positivity is a red flag, how to differentiate diffuse from limited SSc, and why early diagnosis and treatment are essential. What you’ll learn: – What distinguishes diffuse Scleroderma from limited forms – Clinical signs to recognize early: Raynaud’s, skin tightening, telangiectasia – The dangers of steroid use and Scleroderma Renal Crisis – Why collaboration and early referral to SSc centers can save lives – Real stories and clinical pearls from treating high-risk patients This is a must-watch for any clinician managing autoimmune diseases—especially those treating interstitial lung disease, GI complications, or vasculitis related to Scleroderma.
Idiopathic Inflammatory Myopathies and Pulmonary Disorders Including ILD
July 2025
04:59 m
Inflammatory myopathies—like dermatomyositis, polymyositis, and inclusion body myositis—can be difficult to diagnose and manage, especially when they overlap with interstitial lung disease (ILD). In this clinical discussion, Amanda Mixon, PA-C, breaks down what to look for, from subtle signs like "mechanic's hands" to more serious red flags like MDA5-positive rapidly progressive ILD. Special attention is given to anti-synthetase syndrome, a condition often associated with ILD, arthritis, and elevated CK levels, and how antibody testing (e.g., Jo-1, SSA, MDA5) can guide diagnosis and urgency of care. You’ll also learn how to approach cancer screenings in patients with dermatomyositis and why a full malignancy workup is essential. What you'll learn: – How to identify anti-synthetase syndrome and inflammatory myopathies – Key clinical signs: weakness, mechanic’s hands, non-erosive arthritis – Understanding the myositis antibody panel and its clinical utility – The connection between dermatomyositis and malignancy risk – When and how to conduct a thorough cancer screening – Treatments including JAK inhibitors, IVIG, and rituximab Perfect for APPs, pulmonologists, and rheumatology teams, this video empowers you to catch early signs, personalize diagnostics, and take action.
Limited Cutaneous Scleroderma Presentation
July 2025
01:48 m
In this quick but focused clinical overview, Amanda Mixon, PA-C, explains how to identify and differentiate limited systemic sclerosis (also known as CREST syndrome) from diffuse scleroderma. Associated with centromere antibodies, limited scleroderma primarily affects the distal extremities and face, and while skin involvement is less severe, patients face distinct long-term risks—especially pulmonary hypertension. This video breaks down the classic CREST acronym (Calcinosis, Raynaud’s, Esophageal dysmotility, Sclerodactyly, and Telangiectasias), along with practical tips for early recognition and long-term management. What you'll learn: – How to recognize clinical features of limited scleroderma – The role of centromere antibodies vs. SCL-70 in diagnosis – Early signs like Raynaud’s and esophageal symptoms – What to monitor for in years 5–10: pulmonary hypertension, vascular disease – Differentiating CREST from diffuse disease This is an essential update for APPs and clinicians managing autoimmune connective tissue disease, especially in patients with progressive symptoms involving the skin, GI tract, and lungs.
Sjogren’s Disease and ILD
July 2025
01:43 m
In this concise and clinically insightful discussion, Amanda Mixon, PA-C, breaks down what to look for when suspecting Sjögren’s syndrome—an autoimmune condition marked by chronic dry eye and dry mouth, fatigue, and systemic manifestations. Often associated with SSA and SSB antibodies, Sjögren’s can overlap with interstitial lung disease (ILD), making it especially important for pulmonary and rheumatology providers to recognize early. Learn how to distinguish classic symptoms from environmental causes, when to consider antibody testing, and which patients may be at higher risk for more severe complications like ILD. What you’ll learn: – Clinical clues for identifying Sjögren’s in practice – Role of SSA and SSB antibodies in diagnosis – Recognizing extra-glandular manifestations: fatigue, arthritis, rashes – When to suspect ILD in Sjögren’s patients – Medication options and early steroid use considerations Whether you’re in primary care, pulmonology, or rheumatology, this video equips you to ask the right questions and understand the systemic risks behind what may appear to be “just dry mouth.”
Industry Resources
Identifying and Monitoring Autoimmune ILD | Insights in ILD
Pulmonary Function Tests (PFTs) Pocket Guide | Insights in ILD
HRCT Pocket Guide | Insights in ILD
History Taking Pocket Guide | Insights in ILD
WANT EXPERT PERSPECTIVES ON INTERSTITIAL LUNG DISEASE?
Imaging Atlas of Interstitial Lung Diseases | Insights in ILD
Rad Rounds UIP to IPF Mobile Application
Rad Rounds - UIP to IPF is an innovative, peer-reviewed resource that provides practicing and future pulmonologists and radiologists with training and references for recognizing and evaluating usual interstitial pneumonia (UIP) and interstitial lung diseases (ILDs) on high resolution computed tomography (HRCT). Through this application the user can access learning materials such as a step-by-step pattern recognition algorithm, utilizing user-provided HRCT scans, an interactive UIP/ILD glossary and image gallery to further assist in the evaluative process, several “test your knowledge” quizzes, and a series of short informational videos, covering subjects such as: Basic HRCT Technique, Imaging Positions, and Recognizing Features of ILD on HRCT. This app is ideal for: radiologists that would like to use the interactive algorithm to help assess their HRCT scans, pulmonologists that want to evaluate their own cases or learn more about HRCT in the diagnosis of ILD, and medical students and residents that want to learn about HRCT and ILD. Download now and find out: Is It UIP? Available on the App Store: https://apps.apple.com/us/app/rad-rounds-uip-to-ipf/id1327938328 Available on Google Play: https://play.google.com/store/apps/details?id=com.boehringer.radiologyrounds&hl=en_US
The Importance Of Taking A Patient's History In ILD
A Day In The Life Of A Rheumatology App: A Focus On Interstitial Lung Disease
A Day In The Life Of A Pulmonary App: A Focus On Interstitial Lung Disease
News
News
Macrophage in the Crosshairs: Chemical Inhalation and Lung Immune Defense
June 2026
Pulmonary macrophages are central regulators of lung injury and repair following acute inhalation of toxic chemicals. Strategically positioned within the airspaces and lung parenchyma, resident macrophage populations act as first responders that sense epithelial and endothelial injury, initiate sterile inflammatory responses, and coordinate immune cell recruitment, thereby influencing whether injury resolves or progresses to chronic inflammation and fibrosis. Recent advances have revealed...
Long-term safety and pulmonary function stabilization with nintedanib in systemic sclerosis-associated interstitial lung disease, 2020-2025: a real-world retrospective study from a reference centre
June 2026
Randomized trials have demonstrated that nintedanib is beneficial for Systemic Sclerosis-associated interstitial lung disease (SSc-ILD) with an acceptable safety profile. We evaluated the long-term safety and efficacy of nintedanib in a real-world SSc-ILD cohort. Medical records of SSc patients receiving nintedanib for newly diagnosed fibrotic or progressive ILD between 2020 and 2025 in our center were retrospectively reviewed. Forced vital capacity (FVC%) and diffusing capacity for carbon...
Impact of nocturnal oxygen supplementation on sleep quality and daytime fatigue among interstitial lung disease (ILD) patients
June 2026
A collection of more than 300 conditions known as interstitial lung diseases (ILDs) limit oxygen delivery by generating persistent inflammation and irreversible lung tissue scarring, or fibrosis. There is progressive impairment of gas exchange and are frequently complicate by nocturnal hypoxemia. It remains under-recognized despite its significant impact on sleep quality and daytime functioning. Therefore, it is of interest to report the effect of nocturnal oxygen supplementation on sleep...
Trastuzumab deruxtecan (T-DXd) in HER2-expressing gynecological malignancies: Clinical evidence, safety profile, and future directions
June 2026
Endometrial, ovarian, and cervical cancers in advanced or recurrent stages are associated with unfavorable outcomes, emphasizing the need for effective targeted approaches. While HER2 has been identified as a key biomarker in selected high-grade tumors, prior HER2-targeted therapies have yielded inconsistent results. This review discusses the underlying biology, clinical outcomes, safety considerations, and evolving application of trastuzumab deruxtecan (T-DXd) in HER2-positive gynecological...
Clinical course, treatment and outcome of severe pneumocystis pneumonia in patients with autoimmune or inflammatory diseases: a prospective study
June 2026
CONCLUSIONS: PCP is life-threatening in AID patients. Beyond baseline hypoxemia, early follow-up variables, particularly initial treatment failure and progressive pulmonary fibrosis, are critical prognostic indicators, warranting further research to drive understanding of their causes.
Senicapoc in Patients with Idiopathic Pulmonary Fibrosis or Other Progressive Fibrotic Interstitial Lung Diseases: Protocol for a Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Trial
June 2026
Background/Objectives: Idiopathic pulmonary fibrosis (IPF) and other progressive fibrotic interstitial lung diseases (F-ILD) are characterised by progressive loss of lung function, worsening symptoms, and poor prognosis. Current antifibrotic therapies slow disease progression but do not arrest or reverse fibrosis and are frequently associated with adverse effects. Senicapoc, a selective KCa3.1 channel inhibitor, has shown antifibrotic effects in preclinical models, human lung myofibroblasts, and...
Host, Pathogen, and Pulmonary Anatomy in Pneumonia: An Integrated Imaging and Clinical Perspective
June 2026
Pneumonia remains a major global health concern, particularly among elderly and immunocompromised populations, and is associated with substantial morbidity, mortality, and healthcare burden. It is a heterogeneous infectious disease caused by a wide variety of microorganisms, resulting in diverse imaging manifestations and characteristic patterns of pulmonary distribution. Despite advances in microbiological diagnostics and imaging, the literature still lacks a comprehensive overview integrating...
Lung Auscultation for Detecting Interstitial Lung Disease in Patients with Newly Diagnosed Systemic Sclerosis: Retrospective Cohort Study
June 2026
Background/Objectives: Interstitial lung disease (ILD) occurs commonly in systemic sclerosis (SSc) and is the leading cause of mortality. There are limited data on the accuracy of lung auscultation in identifying the presence of ILD in patients with SSc. Methods: We retrospectively identified patients with newly diagnosed SSc who had documented lung auscultation findings and chest high-resolution computed tomography (HRCT) available for review. Diagnoses were made by rheumatologists at Mayo...
Disease Mechanisms and Therapeutic Advances in Idiopathic and Progressive Pulmonary Fibrosis: From Approved Drugs to Emerging Strategies
June 2026
Interstitial lung diseases (ILDs) are frequently characterized by the presence of pulmonary fibrosis (PF), which may lead to respiratory failure secondary to irreversible parenchymal distortion. Although idiopathic pulmonary fibrosis (IPF) is the clinical prototype, the emergence of the progressive pulmonary fibrosis (PPF) phenotype has shifted the therapeutic paradigm toward shared pathogenic pathways while preserving the need to recognize the biological and clinical heterogeneity of the...
Exploratory Real-World Observations on Pulmonary Function Evolution, HRCT Patterns, and Antifibrotic Escalation in Systemic Sclerosis-Associated Interstitial Lung Disease Treated with Mycophenolate Mofetil
June 2026
Systemic sclerosis-associated interstitial lung disease (SSc-ILD) remains an important cause of morbidity and mortality in systemic sclerosis. Mycophenolate mofetil (MMF) is widely used as first-line immunosuppressive therapy; however, real-world descriptions of pulmonary functional and radiologic evolution during MMF therapy remain limited, particularly according to high-resolution computed tomography (HRCT) pattern. Objectives: To descriptively evaluate pulmonary function evolution, radiologic...
A Spatiotemporal Transformer Framework on 4D-CT for Early Prediction of Progressive Pulmonary Fibrosis
June 2026
Progressive pulmonary fibrosis (PPF) remains difficult to predict because static imaging may not fully capture regional respiratory motion, ventilation heterogeneity, and mechanical deformation. We propose a spatiotemporal transformer (ST-Former) framework that jointly models dynamic lung deformation, ventilation, and regional strain from four-dimensional computed tomography (4D-CT). The model integrates CT intensity, deformable registration-derived displacement magnitude, Jacobian-based...
Oxygen therapy in interstitial lung disease - navigating benefit and burden
June 2026
PURPOSE OF REVIEW: Oxygen therapy is a key component of interstitial lung disease (ILD) management. This review summarizes the current evidence and explores how to balance its benefits and burdens in people with ILD.
Multimodal ultrasound for precise quantitative evaluation of diaphragmatic lesions in idiopathic inflammatory myopathy: a promising assessment tool
June 2026
CONCLUSIONS: Multimodal ultrasound enables the early detection and quantitative monitoring of diaphragmatic impairment in IIM. Viscoelastic parameters, particularly the Vi, may aid in the identification of patients with respiratory involvement. Diaphragmatic functional parameters (excursion and the DTF) are responsive to treatment and may serve as objective biomarkers for monitoring the therapeutic response, complementing conventional serological assessments.
Latin American expert opinion paper on the diagnosis and treatment of pulmonary hypertension associated with interstitial lung disease
June 2026
Pulmonary hypertension associated with interstitial lung disease (PH-ILD) represents a major clinical challenge due to its impact on prognosis and the complexity of diagnosis and management. The objective of this work was to develop practical, region-specific guidelines primarily aimed at supporting healthcare professionals in Latin America. A multidisciplinary working group of Latin American experts in PH-ILD developed an expert opinion paper, from which a diagnostic and therapeutic algorithm...
Acute Eosinophilic Pneumonia Triggered by Carbamazepine Therapy: A Clinical and Radiologic Case Report
June 2026
Acute eosinophilic pneumonia (AEP) is a type of interstitial lung disease characterized by eosinophilic infiltration of the lung parenchyma and can present as acute hypoxemic respiratory failure. Certain medications, including carbamazepine, have been rarely implicated in eosinophilic pulmonary syndromes and delayed systemic hypersensitivity reactions with pulmonary involvement. In this case, we report a 50-year-old man who developed acute eosinophilic pneumonia (AEP) characterized by diffuse...
Prevalence of anxiety and depression in idiopathic pulmonary fibrosis: a systematic review and meta-analysis
June 2026
CONCLUSION: The prevalence of anxiety and depression in IPF patients is substantial and is significantly influenced by the assessment tool used: estimates based on ICD-10 clinical diagnoses are substantially lower than those derived from screening tools. Therefore, future large-scale, high-quality studies employing standardized assessment tools are needed to accurately evaluate the psychiatric comorbidity burden in IPF patients, thereby providing robust evidence for the development of targeted...
Window of opportunity with abatacept in Rheumatoid arthritis-associated interstitial lung disease: A multicentre study of 526 patients
June 2026
BACKGROUND: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a major cause of morbidity and mortality, and optimal treatment strategies remain unclear. Abatacept (ABA) is supported by observational evidence, but the impact of early initiation on pulmonary outcomes is unknown.
Progressive pulmonary fibrosis: a state-of-the-art review
June 2026
Fibrosing interstitial lung diseases (ILDs) encompasses a large number of diverse conditions, the prototype being idiopathic pulmonary fibrosis (IPF), characterized by irreversible progression, accounting for loss of lung function, exercise intolerance, and complications especially acute exacerbation and respiratory failure leading to early mortality. A significant proportion of patients with fibrosing ILDs other than IPF will develop a progressive phenotype comparable to IPF. Progression occurs...
Evaluation and Management of Genetic Respiratory Disorders Presenting as Hypoxemic Respiratory Failure in the Newborn Infant
June 2026
Hypoxemic respiratory failure is a common reason for admission to the neonatal intensive care unit for term and late preterm infants. Some infants have rare disorders due to genetic mechanisms including surfactant dysfunction disorders, alveolar capillary dysplasia with misalignment of the pulmonary veins, and other developmental lung disorders that result in more severe, persistent, and even fatal disease. In this article, we summarize clinical characteristics of the most common causes of...
AI-driven discovery of bronopol for the treatment of pulmonary fibrosis via inhibition of fibroblast activation
June 2026
AIMS: Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease with limited therapeutic options. Epigenetic regulation by p300 histone acetyltransferase plays a central role in fibroblast activation and fibrotic gene transcription. This study aimed to identify novel p300 inhibitors from an FDA-regulated compound library using integrated computational approaches and to evaluate their anti-fibrotic potential.
